2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
Target:
In Vivo
In Vitro
Pocapavir acts as a capsid inhibitor, preventing virion uncoating upon entry into the cell. Treatment with Pocapavir is safe and significantly accelerates virus clearance[1]. Pocapavir, an investigational oral antiviral, has been used in a case of neonatal enterovirus sepsis. Pocapavir, also known as SCH 48973 and V-073, is a potent, selective anti-enteroviral agent only available as an emergency investigational drug. Pocapavir belongs to a picornavirus antiviral mechanistic class called capsid inhibitors that block virus uncoating and viral RNA release into cells, which in turn prevents virus replication[2].
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Collett MS, et al. Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model. J Infect Dis. 2017 Feb 1;215(3):335-343.
[2]. Wittekind SG, et al. Neonatal Enterovirus Myocarditis With Severe Dystrophic Calcification: Novel Treatment WithPocapavir. J Investig Med High Impact Case Rep. 2017 Sep 14;5(3):2324709617729393.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
